Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

RObotic Versus LAparoscopic Resection for Rectal Cancer
RObotic Versus LAparoscopic Resection for Rectal Cancer An International, Multicentre, Prospective, Randomised, Controlled, Unblinded, Parallel-group Trial of Robotic-assisted Versus Laparoscopic Surgery for Treatment of Rectal Cancer.
Status: Enrolling
Updated:  11/30/2015
St. Joseph Mercy Health System
mi
from
Ypsilanti, MI
RObotic Versus LAparoscopic Resection for Rectal Cancer
RObotic Versus LAparoscopic Resection for Rectal Cancer An International, Multicentre, Prospective, Randomised, Controlled, Unblinded, Parallel-group Trial of Robotic-assisted Versus Laparoscopic Surgery for Treatment of Rectal Cancer.
Status: Enrolling
Updated: 11/30/2015
St. Joseph Mercy Health System
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
RObotic Versus LAparoscopic Resection for Rectal Cancer
RObotic Versus LAparoscopic Resection for Rectal Cancer An International, Multicentre, Prospective, Randomised, Controlled, Unblinded, Parallel-group Trial of Robotic-assisted Versus Laparoscopic Surgery for Treatment of Rectal Cancer.
Status: Enrolling
Updated:  11/30/2015
Washington University School of Medicine in St. Louis
mi
from
St. Louis, MO
RObotic Versus LAparoscopic Resection for Rectal Cancer
RObotic Versus LAparoscopic Resection for Rectal Cancer An International, Multicentre, Prospective, Randomised, Controlled, Unblinded, Parallel-group Trial of Robotic-assisted Versus Laparoscopic Surgery for Treatment of Rectal Cancer.
Status: Enrolling
Updated: 11/30/2015
Washington University School of Medicine in St. Louis
mi
from
St. Louis, MO
Click here to add this to my saved trials
RObotic Versus LAparoscopic Resection for Rectal Cancer
RObotic Versus LAparoscopic Resection for Rectal Cancer An International, Multicentre, Prospective, Randomised, Controlled, Unblinded, Parallel-group Trial of Robotic-assisted Versus Laparoscopic Surgery for Treatment of Rectal Cancer.
Status: Enrolling
Updated:  11/30/2015
Duke Univ Med Ctr
mi
from
Durham, NC
RObotic Versus LAparoscopic Resection for Rectal Cancer
RObotic Versus LAparoscopic Resection for Rectal Cancer An International, Multicentre, Prospective, Randomised, Controlled, Unblinded, Parallel-group Trial of Robotic-assisted Versus Laparoscopic Surgery for Treatment of Rectal Cancer.
Status: Enrolling
Updated: 11/30/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
RObotic Versus LAparoscopic Resection for Rectal Cancer
RObotic Versus LAparoscopic Resection for Rectal Cancer An International, Multicentre, Prospective, Randomised, Controlled, Unblinded, Parallel-group Trial of Robotic-assisted Versus Laparoscopic Surgery for Treatment of Rectal Cancer.
Status: Enrolling
Updated:  11/30/2015
ARIA Health
mi
from
Philadelphia, PA
RObotic Versus LAparoscopic Resection for Rectal Cancer
RObotic Versus LAparoscopic Resection for Rectal Cancer An International, Multicentre, Prospective, Randomised, Controlled, Unblinded, Parallel-group Trial of Robotic-assisted Versus Laparoscopic Surgery for Treatment of Rectal Cancer.
Status: Enrolling
Updated: 11/30/2015
ARIA Health
mi
from
Philadelphia, PA
Click here to add this to my saved trials
RObotic Versus LAparoscopic Resection for Rectal Cancer
RObotic Versus LAparoscopic Resection for Rectal Cancer An International, Multicentre, Prospective, Randomised, Controlled, Unblinded, Parallel-group Trial of Robotic-assisted Versus Laparoscopic Surgery for Treatment of Rectal Cancer.
Status: Enrolling
Updated:  11/30/2015
Baylor University Medical Center
mi
from
Dallas, TX
RObotic Versus LAparoscopic Resection for Rectal Cancer
RObotic Versus LAparoscopic Resection for Rectal Cancer An International, Multicentre, Prospective, Randomised, Controlled, Unblinded, Parallel-group Trial of Robotic-assisted Versus Laparoscopic Surgery for Treatment of Rectal Cancer.
Status: Enrolling
Updated: 11/30/2015
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Pilot Trial of Opioid Taper Support
Pilot Randomized Trial of Opioid Taper Support
Status: Enrolling
Updated:  11/30/2015
University of Washington Center for Pain Relief
mi
from
Seattle, WA
Pilot Trial of Opioid Taper Support
Pilot Randomized Trial of Opioid Taper Support
Status: Enrolling
Updated: 11/30/2015
University of Washington Center for Pain Relief
mi
from
Seattle, WA
Click here to add this to my saved trials
Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy
Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy
Status: Enrolling
Updated:  11/30/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy
Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy
Status: Enrolling
Updated: 11/30/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Birmingham, AL
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
San Diego, CA
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Denver, CO
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Bradenton, FL
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Daytona Beach, FL
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Fort Myers, FL
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Plantation, FL
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Plantation, FL
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Jeffersonville, IN
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Wichita, KA
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Shreveport, LA
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Omaha, NE
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Syracuse, NY
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Syracuse, NY
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Columbus, OH
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Eugene, OR
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Eugene, OR
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Myrtle Beach, SC
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Dallas, TX
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
San Antonio, TX
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Virginia Beach, VA
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
mi
from
Brighton,
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
mi
from
Brighton,
Click here to add this to my saved trials
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Houston, TX
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Cancer Research Center of Hawaii
mi
from
Honolulu, HI
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Cancer Research Center of Hawaii
mi
from
Honolulu, HI
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Maine Children's Cancer Program
mi
from
Scarborough, ME
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Maine Children's Cancer Program
mi
from
Scarborough, ME
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Spectrum Health and DeVos Children's Hospital
mi
from
Grand Rapids, MI
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Spectrum Health and DeVos Children's Hospital
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Children's Hospital of Omaha
mi
from
Omaha, NE
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Children's Hospital of Omaha
mi
from
Omaha, NE
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Albert Einstein Clinical Cancer Center
mi
from
Bronx, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Albert Einstein Clinical Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Winthrop University Hospital
mi
from
Mineola, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
NYU School of Medicine's Kaplan Comprehensive Cancer Center
mi
from
New York, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
NYU School of Medicine's Kaplan Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Beth Israel Hospital North
mi
from
New York, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Beth Israel Hospital North
mi
from
New York, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
State University of New York Health Sciences Center - Stony Brook
mi
from
Stony Brook, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
State University of New York Health Sciences Center - Stony Brook
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  11/30/2015
Children's Hospital
mi
from
Buenos Aires,
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 11/30/2015
Children's Hospital
mi
from
Buenos Aires,
Click here to add this to my saved trials
The Women's Healthy Lifestyle Study
Motivational Interviewing for Weight Maintenance
Status: Enrolling
Updated:  11/30/2015
University of Michigan
mi
from
Ann Arbor, MI
The Women's Healthy Lifestyle Study
Motivational Interviewing for Weight Maintenance
Status: Enrolling
Updated: 11/30/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  11/30/2015
Billings Clinic
mi
from
Billings, MT
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 11/30/2015
Billings Clinic
mi
from
Billings, MT
Click here to add this to my saved trials
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  11/30/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 11/30/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  11/30/2015
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 11/30/2015
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials